ASPHF (Ascentage Pharma Group International) EBIT: $-166.31 Mil (TTM As of Dec. 2025)

What is Ascentage Pharma Group International EBIT?

Ascentage Pharma Group International ASPHF -3.51% 71 EBIT is $-166.31 Mil as of Dec. 2025. GuruFocus rates ASPHF with a GF Score™ of 71/100 and a GF Value™ of $6.61 (Possible Value Trap). The stock has 7 warning signs investors should review.

Ascentage Pharma Group International's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was $-88.66 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was $-166.31 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Ascentage Pharma Group International's annualized ROC % for the quarter that ended in Dec. 2025 was -60.33%. Ascentage Pharma Group International's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -147.35%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Ascentage Pharma Group International's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -11.52%.

Ascentage Pharma Group International (OTCPK:ASPHF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Ascentage Pharma Group International's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

	ROC % (Q: Dec. 2025 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2025 )	+	Invested Capital (Q: Dec. 2025 ))	/ count )
=	-183.072 * ( 1 - 0% )	/	( (279.746	+	327.115)	/ 2 )
=	-183.072	/	303.4305
=	-60.33 %

where

	Invested Capital		(Q: Jun. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	424.23	-	51.255	-	( 231.387	-	max(0, 172.595	-	265.824	+	231.387	))
=	279.746

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	562.752	-	50.948	-	( 349.898	-	max(0, 233.327	-	418.016	+	349.898	))
=	327.115

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Ascentage Pharma Group International's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2025 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2025		Q: Dec. 2025
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-177.324	/	( ( (121.436 + max(-44.366, 0))	+	(117.737 + max(1.516, 0)) )	/	2 )
=	-177.324	/	( ( 121.436	+	119.253 )	/	2 )
=	-177.324	/	120.3445
=	-147.35 %

where Working Capital is:

	Working Capital		(Q: Jun. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(10.913	+	1.196	+	0.0010000000000332)	-	(51.255	+	5.22	+	0.0010000000000048)
=	-44.366

	Working Capital		(Q: Dec. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(35.912	+	4.063	+	21.299)	-	(50.948	+	8.531	+	0.279)
=	1.516

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Ascentage Pharma Group International's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2025 )
	=	-166.306	/	1443.202
	=	-11.52 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ascentage Pharma Group International EBIT Related Terms

Ascentage Pharma Group International EBIT Historical Data

* Premium members only.

The historical data trend for Ascentage Pharma Group International's EBIT can be seen below:

Ascentage Pharma Group International EBIT Chart

Ascentage Pharma Group International Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EBIT

Get a 7-Day Free Trial

-128.04

-119.68

-117.20

-45.44

-167.82

Ascentage Pharma Group International Semi-Annual Data
	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
EBIT	Get a 7-Day Free Trial													-68.61	27.15	-72.49	-77.64	-88.66

ASPHF vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Ascentage Pharma Group International's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ascentage Pharma Group International EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascentage Pharma Group International's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Ascentage Pharma Group International's EV-to-EBIT falls into.

Save Embed

71GF Score

Ascentage Pharma Group International ASPHF

EBIT is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Ascentage Pharma Group International EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-166.31 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of $-166.31 Mil mean?

Ascentage Pharma Group International (ASPHF) has a EBIT of $-166.31 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Ascentage Pharma Group International.

Is Ascentage Pharma Group International's EBIT too high?

Ascentage Pharma Group International's current EBIT is $-166.31 Mil. Overall, Ascentage Pharma Group International has a GF Score™ of 71/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does Ascentage Pharma Group International's EBIT compare to VRTX and REGN?

Ascentage Pharma Group International's EBIT of $-166.31 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Biotechnology company?

A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Ascentage Pharma Group International. Ascentage Pharma Group International's current EBIT is $-166.31 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Ascentage Pharma Group International stock overvalued right now?

Based on GuruFocus' analysis, Ascentage Pharma Group International (ASPHF) is currently considered Possible Value Trap. The stock's GF Value™ is $6.61, compared to a current price of $4.53 — trading 31.5% below its estimated fair value. The current EBIT is $-166.31 Mil. Ascentage Pharma Group International's overall GF Score™ is 71/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For Ascentage Pharma Group International (ASPHF), the current EBIT is $-166.31 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ascentage Pharma Group International (ASPHF) Overvalued in 2026?

Based on GuruFocus' analysis, Ascentage Pharma Group International stock appears to be undervalued. The current stock price of $4.53 is trading 31.5% below its estimated GF Value™ of $6.61. GuruFocus considers Ascentage Pharma Group International to be Possible Value Trap.

Key valuation signals for ASPHF:

EBIT: $-166.31 Mil
GF Value™: $6.61 vs. price of $4.53 (31.5% below fair value)
GF Score™: 71/100 with 7 warning signs

No single metric tells the full story. See the ASPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ascentage Pharma Group International Business Description

Industry Healthcare Biotechnology

Comparable Companies HKSE:02617 HKSE:01672 HKSE:09887 HKSE:02595 HKSE:07666 HKSE:02162 HKSE:06872 HKSE:01952 HKSE:09606 HKSE:02171 VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges AAPG:USA 06855:Hong Kong 36X0:Germany

Address 68 Xinqing Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215000

Website https://www.ascentage.cn

Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.

71GF Score

Get the complete analysis for ASPHF

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.53

Price

$6.61

GF Value

View ASPHF Analysis

See EBIT data for all stocks →